Research Article

Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson’s Disease Model

Bharti Gaba,1 Tahira Khan,2 Md Faheem Haider,1 Tausif Alam,1 Sanjula Baboota1, Suhel Parvez3, and Javed Ali1

1Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India
2Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India
3Department of Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India

Correspondence should be addressed to Javed Ali; javedaali@yahoo.com

Received 16 December 2018; Accepted 13 March 2019; Published 14 April 2019

Academic Editor: Kamla Pathak

Copyright © 2019 Bharti Gaba et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. The present study is an attempt to develop a vitamin E loaded naringenin (NRG) Nanoemulsion (NE) for direct nose-to-brain delivery for better management of Parkinson’s disease (PD).

Methods. The optimized NE was evaluated for efficacy in PD using multiple behavioral studies (including narrow beam test, muscular coordination test, grip strength test, forced swimming test, and akinesia test) in a rat model. Optimized formulation was evaluated for droplet size, polydispersity index (PDI), refractive index, transmittance, zeta potential, and viscosity.

Results. Optimized NE had a droplet size of 38.70 ± 3.11 nm, PDI of 0.14 ± 0.0024, refractive index of 1.43 ± 0.01, transmittance of 98.12 ± 0.07 %, zeta potential of −27.4 ± 0.14 mV, and viscosity of 19.67 ± 0.25 Pa s. Behavioral studies showed that 6-OHDA induced PD in rats were successfully reversed when administered with NRG NE intranasally along with the levodopa. While the levels of GSH and SOD were significantly higher, levels of MDA were significantly lower in the group treated with NRG NE via intranasal route along with levodopa.

Conclusion. Encouraging results from current study provide evidence for possible efficacy of a novel noninvasive intranasal delivery system of NRG for management of PD related symptoms.

1. Introduction

Approximately 6.3 million people are affected from Parkinson’s disease (PD) as suggested by World Health Organization. In 2016, 6.1 million individuals worldwide had Parkinson’s disease, of whom 2.9 million (47.5%) were women and 3.2 million (52.5%) were men. The number of individuals with Parkinson’s disease in 2016 was 2.4 times higher than in 1990 (2.5 million, 95%). This increase was not solely due to the increasing number of older people because global age-standardized prevalence rates increased by 21.7% from 1990 to 2016 compared with an increase of 74.3% for crude prevalence rates. The increase in age-standardized prevalence rates between 1990 and 2016 was similar in men (21.4%) and women (19.3%). Age-standardized prevalence rates of Parkinson’s disease by country varied greater than five times, with the highest rates generally in high-income North America and lowest rates in sub-Saharan Africa [1]. Among the other neurodegenerative diseases, PD is ranked as second most prevalent disorder across the world. It generally affects the middle age or elderly population and is characterized by symptoms related to dopamine deficiency such as resting tremors, muscular rigidity, bradykinesia, postural instability, and disturbance in gait [2, 3]. There are various different endogenous and exogenous reasons accountable for this disease including oxidative stress, heredity, mitochondrial dysfunction, aging, inflammation, and various neurotoxins. Oxidative stress (OS) emerges to be the leading cause of PD. More specifically dopamine is metabolized due to oxidative stress into hydrogen peroxide and other reactive oxygen species (ROS). The treatment available for PD therefore usually aims to correct dopamine deficiency. For the treatment of
PD, levodopa has been widely used as the first line treatment owing to its potential of controlling the motor dysfunction symptoms leading to the successful crossing of blood–brain barrier (BBB). However, using levodopa for the long-term may lead to various motor deficits including disturbances with balance, gait, speech, and posture [4].

Fruits and vegetables typically contain flavonoids, which are the nonnutrients, present in addition to vital vitamins and nutrients present in them. Chemically flavonoids are a collection of polyphenolic compounds distinguished via a benzene-g-pyrene structure. Approximately 4000 flavonoids species have been described which are further categorized into flavones, isoflavonones, anthocyanidins, flavonols, catechins, and flavanones [5–7]. Recently flavonoids have gained attention due to their anticancer, antioxidant, antiviral, and anti-inflammatory properties. One of the citrus flavanone naringenin (NRG) (4',5,7-trihydroxyflavanone) occurs copiously in citrus fruits such as grapes, grapefruit, blood orange, lemons, pummelo, and tangerines [8]. NRG has been reported to display variety of effects on the biological system including like anti-inflammatory, antioxidant, antifibrogenic, antiatherogenic, and anticancer. The advantageous effect of NRG is basically due its antioxidant activity. It has the ability to scavenge oxygen-free radicals and chelate metals that inhibit enzymes to thwart oxidation of low-density lipoproteins. However NRG has some limitations including its poor bioavailability and water insolubility [9,10].

Due to several challenges with use of existing dopaminergic medications for PD, various new formulations have been envisaged for drug delivery directly to the brain through olfactory and trigeminal neuronal pathways instead. There are many invasive and noninvasive techniques that may be used for the brain delivery, out of which intranasal route of drug delivery which is noninvasive and delivery is directly to the brain has been extensively scrutinized. Delivery of lipophilic drug directly to brain in the form of Nanoemulsion (NE) via intranasal route has been found to be one of the best possible approach [11,12]. In addition, solubility of the lipophilic drugs is also enhanced which ultimately improves its permeation across mucosa [13]. NEs are dispersions of two immiscible phases; it may be transparent or translucent having nanometric size ranging between 20 and 200 nm. On the whole, NEs are kinetically stabilized isotropic systems which by using surfactant or mix of surfactant along with a cosurfactant immiscible liquid are made miscible to form a single phase [14,15]. In addition, they possess the advantage over macroemulsion of having free energy and elevated surface area; also it is stabilized against creaming, sedimentation, coalescence, and flocculation [13]. NEs can be formulated with low quantities of emulsifier having approximately 4–10 wt%, hence minimizing surfactant related toxicity problems [16].

Intranasal drug delivery has several advantages over other route of deliveries due to the presence of direct connection between the nasal cavity and central nervous system (CNS). Intranasal route has been extensively studied as an unconventional, convenient, and noninvasive route to deliver the lipophilic drug directly to the brain bypassing the BBB and ultimately enhancing the concentration of drug in the CNS [17, 18]. This route is believed to be highly vascularized and permeable routes having a large surface area and high total blood flow per cm². In addition, quick onset of therapeutic action is created by the rapid absorption of drug due to the low levels of enzyme [19]. In addition, as the drug's systemic exposure is reduced by using the intranasal route it directly dwindles the systemic side effects. Limitations of this route are the delivery of an explicit quantity of formulation, which is 25–200 μl, poor nasal permeability, and rapid mucociliary clearance. These problems can be overcome by the addition of chemical penetration enhancers or colloidal drug delivery systems may be used namely nanoparticles, liposomes and NEs. Based on the existing evidence regarding PD related symptoms caused due to oxidative stress, the delivery of an effective antioxidant via intranasal route will result in higher therapeutic concentration of antioxidant in brain, thereby reducing PD symptoms.

From the previous studies, the effect of vitamin E in conjunction with an additional antioxidant was established for neurodegenerative disorder like Alzheimer's disease [20]. Also, intranasal route for the effective brain delivery was also investigated and proven to be beneficial [20,21]. Hence, main aim of the present work is to develop a vitamin E loaded NRG NE to be given via intranasal route for the direct and effective brain delivery for PD. In the addition, the current study also examined the synergistic effect of vitamin E and NRG in in vivo behavioral studies when administered intranasally on behavioral dysfunction in a 6-OHDA induced rat model of PD. The delivery of naringenin to brain by NRG NE was also determined by estimating NRG levels in brain homogenate and estimation of various pharmacokinetic parameters.

2. Materials and Methods

2.1. Materials. NRG and 6-OHDA were purchased from Sigma Aldrich (St. Louis, MO, USA). Oils such as peanut oil and olive oil were purchased from Loba Chemie (Mumbai, India). From Gattefosse (Saint Priest, Cedex, France) other oils such as capryol 90, Labrafac, capmul, peceol, Polyethylene glycol 400, Transcutol-HP, Captex 200-P, and Sorbitan sesquioleate were procured. From Hi-media laboratories Pvt. Ltd. (Mumbai, India) dialysis membrane-70 (molecular weight cut-off: 12,000–14,000 Da), LA 393-1 MT was purchased. Tween 80, Castor oil, and HPLC grade methanol were procured from Merck (Schuchardh, Hokenbrunn, Germany). Vitamin E was procured from Evion Capsules available in market. Water and methanol were bought from Fischer Scientific Co. (Mumbai, India). Every chemical and solvent used throughout the study were of analytical grade.

2.2. Methods

2.2.1. Method of Analysis by HPLC. NRG was assayed by HPLC using a system consisting of a quaternary LC-10AT VP pump equipped with UV/VIS detector, SPD-10AVP column oven (Shimadzu), a Rheodyne injector, and chromatography data system software (CLASS-VP Ver 6.14 SP1). Chromatographic separation was carried out on column
were placed under continuous shaking using vortex mixer (Nirmal International, Delhi, India) at 25 °C for 24 h. The vials containing the resultant mixtures were then centrifuged at 4500 rpm for 20 min to separate the insoluble drug. The obtained supernatant was filtered to determine the consequence of temperature variations on its stability. All measurements were done in triplicate [25, 26].

2.5.2. Centrifugation Study. To detect any creaming, cracking or phase separation NRG NE was centrifuged for 30 mins at 5000 rpm. All measurements were done in triplicate [25, 26].

2.5.3. Freeze Thaw Cycle. NRG NE was exposed to varied temperatures (4°C and 45°C for not more than 48 h) to determine the effect of temperature on its stability. All measurements were done in triplicate [25, 26].

2.6. Refractive Index and Viscosity. Few drops of the NRG NE were placed on the slide to measure the refractive index (RI) using an Abbe refractometer, which is standardized using castor oil. All measurements were done in triplicate. Brookfield DV III ultra V6.0 RV cone and plate viscometer (Brookfield Engineering Laboratories, Inc., Middleboro, MA) was used to measure the viscosity of the NRG NE without dilution. All of the measurements were carried out using Rheocalc V2.6 software at 25 ± 0.5°C temperature [12].

2.7. Globule Size and Surface Charge Analysis. Globule size, zeta potential and polydispersity index (PDI) of NE were determined using a zetasizer (Nano-ZS90, Malvern Instruments, Worcestershire, UK). Before each measurement, all the formulations were diluted using deionized distilled water for about 200 times. These were then subjected to vigorous shaking for minimizing the multiple scattering effects. 1 ml aliquot from this mixture was pipetted out which was then added on the sample cell for the measurement of average globule diameter. Light scattering was measured at 25°C at
90° angle. Afterwards, 1 ml of each sample was taken into clear polystyrene cuvettes independently for the determination of globule size. All measurements were then done in triplicate [27, 28].

2.8. Measurement of pH. Optimized NE’s pH was calculated by using a pH meter (EUTECH Instruments, Singapore) at 25 ± 2°C in triplicate [29].

2.9. Transmission Electron Microscopy (TEM). Using transmission electron microscope (TEM) (CM 200, Philips Briarcliff Manor, NY, USA) operating at 200 KV, surface morphology of NRG NE was studied. NE was adequately diluted with water (1:1000) and a drop was applied to a 300 mesh carbon coated copper grid of 400 mesh. Further, it was stained with phosphotungstic acid (PTA) (2 % (w/v)) and leaving as such for 1 min to air dry. The dried grid was further examined for size, character, and form of NE [12].

2.10. In Vitro Release Study. In vitro release studies were executed to evaluate the release of NRG from NE formulation with that of the NRG suspension. Trials of NRG NE (2 ml; containing 40 mg/ml of NRG), along with a NRG suspension (2 ml; containing 40 mg/ml of NRG), were carried out using a dialysis membrane method. The dialysis bag (having 12 000 g/mol molecular weight) was pretreated as per the provided standard method and the apparatus was set at 100 rpm maintained at 37 ± 2°C over a magnetic stirrer (Remi Instrument Ltd., Mumbai, India). 2 ml of each formulation was placed in different bags and dipped in 100ml of phosphate buffer pH 6.4 as this corresponded to the pH of nasal fluid. 1 ml of the sample was withdrawn at different time points (0, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 360, and 420 min), and the same amount of fresh media was added to maintain sink conditions. Samples were analyzed for NRG content. The samples were examined at 322 nm by UV spectrophotometer (Shimadzu Corp, Kyoto, Japan) after appropriate dilution. All measurements were done in triplicate.

2.11. Ex Vivo Nasal Mucosa Permeation Study. Ex vivo permeation studies were carried out using a Franz diffusion cell (15.2 ml receiver volume). NRG NE was compared with the NRG suspension using on freshly isolated goat nasal mucosa collected from slaughter house. The goat mucosa was stored in a 10% formalin solution in a deep freezer (−80°C) till further use. Nasal membrane was carefully detached and was wiped with isopropyl alcohol making it free from adhered tissues. 0.2 mm thick tissue was taken and mounted between the donor and receiver compartment of the Franz diffusion cell. Tissue was mounted so that mucosal side should face the donor compartment while the dermal side will be faced on the receiver compartment. Using dissolution medium in the running media (phosphate buffer pH 6.4), mucosa was made stabilized. It was repeated for 10 times by changing the media after each run at 37 ± 1°C. 1 ml of the selected NRG suspension and NRG NE was placed onto each donor compartment, respectively. At different time points (0, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 360, and 420 min) samples were withdrawn and the same amount of fresh media was added. Samples were then analyzed for content of NRG. After appropriate dilution, using UV spectrophotometer (Shimadzu Corp, Kyoto, Japan) samples were investigated at 322 nm. All measurements were done in triplicate.

2.12. Antioxidant Activity (DPPH Method). This test is based on the free radical scavenging activity of the stable DPPH free radical. In DPPH assay method, ascorbic acid (AA) was considered to be a standard antioxidant. Antioxidant activity of vitamin E, NRG NE, and NRG suspension were compared with that of AA. Vitamin E, NRG suspension, and NRG NE and AA were diluted using methanol in a serial dilution from 1–25 µg/ml. 1 ml of DPPH solution (0.004% w/v) in methanol was added to 1 ml of each sample. After 30 min, using blank as methanol absorbance was measured at 515 nm [20]. Following formula was used to calculate the percentage inhibition:

\[
\% \text{ Inhibition} = \frac{A_0 - A_1}{A_1} \times 100
\]

In the above equation, \( A_0 \) signifies the blank’s absorbance and \( A_1 \) signifies the drug solution’s absorbance. Further a plot was constructed between mean % inhibition and log concentration. By interpolation using a graph pad (Prism 6 software, San Diego, California), 50% inhibitory dose (IC50 value) was calculated which was then compared against the standard.

2.13. Pharmacokinetic and Brain Targeting Study. For the pharmacokinetic studies, Wistar rats of either sex, ageing between 11 and 12 weeks and weighing between 200 and 250 gm were taken. Institutional Animal Ethical Committee (AEC), Jamia Hamdard, New Delhi, India, has approved the animal study protocol (173/Go/Re/ S/2000/CPCEA; Approval no. 1176, 2015). Guidelines provided by the AEC were followed during the studies. Further, the animals were divided into different 3 groups, i.e., Groups A, B, and C (each group having 3 rats). Group A was administered with NRG solution via intranasal route (dose 0.72 mg/kg/day dissolved in 0.5 ml of normal saline solution); Groups B and C were administered with NRG NE via intranasal route and intravenous route (dose equivalent to 0.72 mg/kg/day), respectively. Blood samples (0.2 ml) were collected by cardiac puncture and the animals were sacrificed at 0.5, 1, 2, 4, and 8 h time intervals. The blood samples were collected in the microcentrifuge tubes containing EDTA (an anticoagulant) which were then centrifuged for 20 min at 5000 rpm. The supernatant so obtained was stored in deep freezer (−70 ± 10°C) for further HPLC estimation. After collection of the brain it was washed with normal saline to make it free from adhering tissue/fluid. Then it was placed in methanol. Concentration of the drug in brain and plasma was estimated using pharmacokinetic software (PK Functions for Microsoft Excel, Pharsight Corporation, Mountain View, CA). Various parameters like AUC, \( C_{\text{max}} \) \( T_{\text{max}} \), DTE % (drug targeting efficiency), and DTP % (direct transport percentage) were further calculated. \( C_{\text{max}} \) (maximum plasma concentration)
and $T_{\text{max}}$ (time required to reach the maximum concentration) were estimated directly from the real plasma profiles. By using linear trapezoidal method, AUC (area under curve) was computed [29, 30]. The brain targeting efficiency was estimated by the use of following equations:

**Drug targeting efficiency (DTE%)**

$$DTE\% = \frac{(AUC_{\text{brain}}/AUC_{\text{blood}})_{i.n.}}{(AUC_{\text{brain}}/AUC_{\text{blood}})_{i.v.}} \times 100$$

**Drug transport percentage (DTP%)**

$$DTP\% = \frac{B_{i,n} - B_{x}}{(AUC_{\text{brain}}/AUC_{\text{blood}})_{i.v.}} \times 100$$

where $B_x$ is the brain AUC fraction contributed by systemic circulation through the BBB following the i.n. administration which is calculated as follows:

$$B_x = \left( \frac{B_{i,n}}{P_{i,n}} \right) \times P_{i.n.} \quad (3)$$

$B_{i,v}$ and $P_{i,v}$ are the AUC$_{0-\infty}$ for brain and Plasma following intravenous administration, respectively.

$B_{i,n}$ and $P_{i,n}$ are the AUC$_{0-\infty}$ for brain and plasma following intranasal administration, respectively.

The $%F$ (percentage absolute bioavailability value) of the i.n. formulations was calculated as follows:

$$%F = \left( \frac{AUC_{i,n}}{AUC_{i.v.}} \right) \times \frac{Dose_{i,n}}{Dose_{i.v.}} \times 100 \quad (4)$$

### 2.14. Biodistribution Studies

Confocal laser scanning fluorescence microscopy (CLSM) using a fluorescent dye (i.e., ROD-123) was used to study the biodistribution of NRG NE and NRG solution. This fluorescent dye is used as it has less capability to cross the BBB even when given via intravenous route. For using the dye in the formulation, firstly ROD-123 was dissolved in ethanol (20 mg/ml) which was further blended with the formulation (0.175% w/v). Wistar rats of either sex with weight between 200 and 250 g were selected which were further divided into 3 groups (each group consisting of 3 animals). Group I was given ROD-123 loaded NRG solution via intranasal route, and Groups II and III were loaded with ROD-123 NEs via intranasal and intravenous route, respectively. Using cervical dislocation method, animals were humanely sacrificed at 0.5 h after which brain was dissected. The brain was made free from the adhering tissue/fluid by washing it twice using normal saline. Using a microtome, brain was cut into 5μm thickness to get it fixed in 4% (w/v) formaldehyde solution on a slide which was stored at 4°C before the commencement of CLSM studies. These slides were further examined by means of a fluorescence microscope (Olympus FluoView™ FV 1000, CA, USA). Red fluorescent dye ROD-123 leaves the red fluorescent spots which were judged as the noticeable markers of the drug entrenched in NEs [20].

### 2.15. Nasal Ciliotoxicity Studies

Freshly isolated nasal mucosa of goat was obtained from slaughter house and was kept in phosphate buffered saline (PBS pH6.4) to perform the nasal ciliotoxicity studies. Nasal mucosa was divided into 3 sections of homogeneous thickness (0.2 mm). Mucosa was then mounted on Franz diffusion cell. Out of the 3 mucosal pieces first piece of mucosa (M1) treated with isopropyl alcohol will serve as a positive control, second piece of mucosa (M2) was treated with PBS of pH6.4 (serving as negative control) and the third mucosal piece (M3) was treated with drug loaded optimized NE. After 2 h of treatment, samples were rinsed with PBS (pH6.4) appropriately which were further stored 10% formalin to be carried to the pathological laboratory for the slide preparation. A 5 μm thick mucosal piece was cut with the help of a microtome which was then stained with hematoxylin and eosin. Further, the pieces were studied under light microscope joint with an image processor (Motic, Nagoya, Japan) at a magnification of 40x. They were studied for the toxicity to nasal mucosa and the images were documented [31, 32].

### 2.16. Pharmacodynamic Studies

#### 2.16.1. Animals and Treatments

The rats (weighing 200-300 gm) were randomly divided into 5 groups (each group having 6 animals); namely, Group A was treated with normal saline via intranasal route served as a control, Group B was a 6-OHDA induced group again treated with normal saline intranasally served as lesioned control group (PD Model), Group C was a 6-OHDA induced group treated with NRG NE intranasally, Group D was 6-OHDA induced group treated with marketed formulation (levodopa) orally, and Group E was 6-OHDA induced group treated with NRG NE intranasally along with oral levodopa. Rats were anesthetized using ketamine/xylazine cocktail (0.1 mL/20grat wt. IP). The duration of anesthesia was 20-30 minutes. To validate the adequate anesthesia depth, corneal and gross motor reflexes were monitored. The animals were held onto a stereotaxic frame (dual manipulator model 51600 Stoelting Co., IL, USA). Nonpuncture ear bars of 45 mm having a nose bar position of 2.3 mm beneath the interaural line were used. Animals were mounted on a stereotaxic stand and a slight incision was made of skull's skin for the skull for the exposure. The striatum coordinates were calculated precisely as for rat 1.0 mm of anteroposterior (AP), lateral (L) 2.5 mm to the right side, dorsoventral (DV) 4.5 mm relative to bregma, and ventral from dura with the tooth bar set at 0 mm. Subsequently, rats were lesioned into the right striatum and were injected with 10 μg 6-OHDA/2μL mixed with 0.1% ascorbic acid-saline. Group A was injected with 2.0 μl of the vehicle only i.e., 0.1% ascorbic acid-saline. Automatic microdrilling machine was used which was attached on stereotaxic apparatus to made Burr holes in skull for injecting the vehicle at a rate of 0.5 μl/min manually using a Hamilton syringe. After the injection needle was held in the same place for further 5.0 min allowing the toxin to diffuse away from the lesion site. Recovery from anesthesia approximately took 4–5 h. Individual cages were used to keep the treated rats in a well aerated room at 25±2°C until they gain full consciousness.
Afterwards they were housed together in groups as specified above [33].

2.16.2. Narrow Beam Maze (NBM) Test. Animals from all the groups were trained on a narrow beam maze before the lesioning for their balance and motor coordination. NBM consists of a start-and-goal box having 13 cm width and 40 cm high walls and a wooden narrow beam runway of 180 cm in length and 2 cm in width. The beam was made 1 meter elevated from the ground with extra supports. The inner walls of the start-and-goal box were painted black. For 3 consecutive days, animals were tested on NBM for 10 trials per day, each trial having interval of 1 min. During the experiment food pellets were placed in the goal box for the motivation of animals. The time taken by the animals to reach the goal box from the start box was noted [34]. The same procedure was repeated on the 16th day after lesioning for 1 day and time taken by the animals to complete their journey from start box to the goal box was measured. After 27 days of lesioning, animals were treated as per the schedule and the same procedure was repeated and time was noted.

2.16.3. Muscular Coordination Test. To study the motor-coordination ability, the rotarod experiment was performed. Animals from all the groups were trained before the lesioning on rotarod apparatus, i.e., rotarod unit (Omni Rotor, Omnitech Electronics, Inc., Columbus, OH, USA). Rats were allowed to retain on a rotating rod having 75 mm diameter. The retained time for each animal on the rotating rod was recorded having minimum interval between each of 5 min and maximum trial length of 180s. The trials were done in triplicate. The time in tenths of a second was automatically recorded by the apparatus till the rat falls on the floor. The score was presented as mean of latencies of speed was set at 10 rotations per minute having 180 s as cut-off time. The score was presented as mean of latencies of three trials on the rotating rod [34]. Data were accessible as retention time on the rotating bar over the three test trials. After lesioning the same procedure was repeated on the 16th day and after 27 days. Animals were treated as per the schedule and the same procedure was repeated and time was noted.

2.16.4. Forced Swimming Test. Animals from each group were trained for swimming test by placing each rat in a bucket (46 cm diameter X 60 cm height) filled with fresh water (temperature: 28 ± 2°C) 30 cm deep. Data like the mean swimming time, climbing time (trying to climb the wall of bucket), and immobility time (staying afloat and exhibiting minimum movements) were recorded [35]. After lesioning the same procedure was repeated on the 16th day and after 27 days. Animals were treated as per the schedule and the same procedure was repeated and time was noted.

2.16.5. Grip Strength Test. The string test was used to measure grip strength and limb impairment. The apparatus consists of a string measuring approximately 50 cm in length which is pulled tight between two vertical supports and at a height of 40 cm from a flat surface. The rats were made to hang on the string at midway and then scored per the mentioned scale.

If the rat was unable to hang and fall off, it will be given 0; if the rat hangs onto string by two forepaws, it will be scored as 1; if the rat hangs onto string by two forepaws trying to climb on string, it will be marked as 2; if the rat hangs onto string by two forepaws along with one or both hind paws, it will be scored 3; if the rat hangs onto string by all forepaws along with tail wrapped around the string, then it will be given 4 score; and if the rat manages to escape the string, it will be scored as 5. The results were expressed as the total score [36]. The rats were trained for 3 times a day for 3 days. After lesioning the same procedure was repeated on the 16th day and after 27 days. Animals were treated as per the schedule and the same procedure was repeated and time was noted.

2.16.6. Akinesia Test. The delay in initiating the movement may be estimated via performing the akinesia test. This is a general abnormality in motor function in PD. The test is very simple, rapid, and easy to conduct. Also, it is helpful in giving the information related to the upper limb motor function. The test was commenced as described by Olsson and coworkers and the latency was recorded in terms of time needed (in seconds) by rat to initiate the movement. The test was concluded when latency surpasses 180 s [29]. The time taken by each animal to initiate movement for all four limbs was observed and recorded.

2.16.7. Biochemical Estimation

Tissue Preparation. Brain tissue is used to study the enzymatic activity. 200 mg of brain from each rat was extracted and was subjected to homogenization for 3 minutes with the help of a tissue homogenizer. It gives 10 % (w/v) homogenate in 0.1 M potassium phosphate buffer (pH 7.4) containing 1 mM ethylenediaminetetraacetic acid (EDTA). Further this homogenate was centrifuged for 5 min at 800 rpm at 4°C to separate the nuclear debris. Supernatant so obtained was again subjected to centrifugation for 20 min at 4°C at 10,500 rpm so that a postmitochondrial supernatant (PMS) is obtained.

Glutathione (GSH) Estimation. GSH was estimated as the total nonprotein sulphydryl groups, 5,5'-dithio- (2-nitrobenzoic acid) (DTNB) is reduced by the –SH groups of GSH to form one mole of 2-nitro-5-mercaptopbenzoic acid per mole of –SH. The intense yellow color of the released nitromercaptobenzoic acid anion was used to measure –SH groups present in the brain homogenate. The mixture was then shaken for 15 min and was subjected to centrifugation at 3000 rpm for 15 min. After the centrifugation, supernatant was separated out from which 2 mL of was mixed with 4 mL of 0.02M EDTA solution which was further diluted with 1.6 mL of distilled water and 0.4 mL of 50% trichloroacetic acid (TCA) solution. The mixture was then shaken for 15 min and was subjected to centrifugation at 3000 rpm for 15 min. After the centrifugation, supernatant was separated out from which 2 mL of was mixed with 4 mL of Tris buffer (0.4 M, pH 8.9) and 0.1 mL of DTNB solution. The obtained yellow colored complex was studied at 412 nm spectrophotometrically and
the content for GSH content was articulated as micromoles of GSH per milligram of protein [29].

**Thiobarbituric Acid-Reactive Substances (TBARS) Estimation.** Estimation of lipid peroxidation rate was done by mixing 2 mL of potassium chloride (0.15 M) with 2 mL of 10% brain homogenate. It was then homogenized for 3 min using a tissue homogenizer. 1 mL of the homogenate was pipetted out in a test tube with further addition of 0.5 mL TCA (30%) followed by 0.5 mL thiobarbituric acid (TBA, 0.8%). Mixture so obtained was kept in a water bath for 30 min at 80°C followed by keeping it in ice cold water for the next 30 min. This mixture was again subjected to centrifuge for 15 min at 3,000 rpm for 15 min. Supernatant so obtained was collected in a test tube with further addition of 0.5 mL of folin reagent which was estimated at 750 nm spectrophotometrically after 30 minutes [29].

**Superoxide Dismutase (SOD) Estimation.** A quantity of 2 mL of 10% of the brain homogenate was mixed with 2 mL of the potassium phosphate buffer pH 7.4. The prepared mixture was centrifuged for 10 min to maintain the temperature at 4°C followed by keeping the supernatant at room temperature for 30 min. This mixture was again subjected to centrifuge for 15 min at 5000 rpm for 15 min. Supernatant so obtained was made to rest at room temperature for 30 minutes [29].

### 2.17. Statistical Analysis.

All samples used in the study were freshly prepared and the experiments were carried out in triplicate. Statistical analysis of data was carried out using computer software graph pad Prism 7.0 (Graph Pad Software San Diego, CA). All experimental data were reported as mean ± standard deviation (SD). One-way ANOVA followed by Dunnett's t-test was used for analysis of the result. The statistical implication level was set at p < 0.05.

### 3. Results and Discussion

#### 3.1. Analytical Methodology.

The retention time of NRG was found at 8.34 min. By using the standard deviation method, limit of detection (LOD) and limit of quantification (LOQ) were calculated and found to be 23.34 ng/mL and 67.88 ng/mL, respectively.

#### 3.2. Excipients Selection.

Oil being the solubilizing agent for lipophilic drugs is the chief component in formulating the NE. The drug should be freely soluble in the oil to avoid any forced solubility which may result in drug's precipitation above a time period. Solubility studies demonstrated that NRG is highly soluble in the combination of Capryol 90: vitamin E (1:1), i.e., 152.98 ± 2.42 mg/ml (Figure 1). Vitamin E was selected as it along with serving as an oily phase may also boost the antioxidant activity. Surfactant selection is also a critical parameter such that decreasing the interfacial tension the concentration should not cause any toxicity [37]. Based on this, nonionic surfactants are generally considered to be less toxic than the ionic surfactants [38]. On the basis of solubility and miscibility studies, Tween 80 was selected as the surfactant to be used. In addition to belonging to a nonionic class of surfactant Tween 80 is also less distressed by ionic strength and pH (Figure 1). Surfactant alone is unable to achieve the transient negative interfacial tension and fluid interfacial film, because of which a cosurfactant needs to be added as it reduces the bending stress making the interfacial film flexible. Based on the miscibility studies, Transcutol-HP was selected as the cosurfactant (Table 1). All the chemicals used in the study were nonirritant and nonsensitizing to the skin. Also, the chemicals were pharmaceutically acceptable and were generally regarded as safe (GRAS category) for use.

#### 3.3. Pseudoternary Phase Diagram Construction.

Using aqueous phase titrations, pseudoternary phase diagrams were constructed to determine the surfactant to cosurfactant ratio competent of constructing the largest isotropic NE region. Pseudoternary phase diagram were constructed using oil phase of capryol 90: vitamin E (1:1), Tween 80 as the surfactant along with cosurfactant as Transcutol-HP and aqueous phase as distilled water. The area of NE was found in order of $S_{mix}$ 4:1 > 3:1 > 2:1 > 1:1 > 1:0. It was observed that the small or large area of NE is directly dependent on the $S_{mix}$ ratio and its ability to solubilize the oil phase along with decreasing free energy of the system. From the figure it was observed that less NE area is shown in the $S_{mix}$ ratio 1:1 followed by 1:2 (Figure 2). As compared to the $S_{mix}$ ratios 2:1 and 3:1, 4:1 showed the maximum NE region based on its ability to solubilize the oil phase while decreasing the system's free energy indicating the increasing emulsification with increasing concentration of surfactant. On further increasing the $S_{mix}$ ratio to 5:1 it was observed that area was slightly decreased signifying that the further addition of the surfactant does not contribute to the emulsification process. Hence, 4:1 of the $S_{mix}$ was selected as the NE region.

#### 3.4. Physical Stability Testing of NEs.

NEs are the thermokinetically stable systems which are prepared at a particular concentration of $S_{mix}$, oil separation and water. The formulation so prepared should be devoid of creaming, cracking and phase. As mentioned earlier the chosen formulations were passed through different stress conditions, namely, heating-cooling cycle, freeze thaw cycle, and centrifugation (Table 2). Results demonstrated that the formulations prepared from the $S_{mix}$ ratio of 1:2 and 1:3 was not able to pass the stress test performed to assess the physical stability owing to the formulation's insufficient emulsification. A number of formulations turn turbid, the possible reason of which might be Ostwald ripening.

#### 3.5. Preparation of Drug Loaded NE.

For the preparation of the drug loaded formulation, NRG was dissolved in the oil phase. This was followed by addition of the required quantity
of $S_{\text{mix}}$ and drop wise addition of distilled water until a clear and transparent liquid was attained (Table 3).

3.6. Globule Size and Surface Charge Analysis. Optimized NE was transparent and monophasic having the mean globule size of 38.70 $\pm$ 3.11 nm ($n=3$) having a uniform PDI of 0.14 $\pm$ 0.0024 (Figure 3(a)). It may be due to the larger emulsification area provided by the $S_{\text{mix}}$. The higher the concentration of the surfactant stronger is the stabilization because of the closely packed surfactant film present at the oil-water interface. This suggests that the surfactant has more important role to play in nanoemulsification of the oily mixture than the cosurfactant. Also, lesser the PDI better is the size distribution of the globules along with the stability of the formulation [39]. Optimized formulation had a zeta potential of $-27.4 \pm 0.14$ mV indicating good dispersion stability and also ensuring the creation of a high-energy barrier against coalescence of the dispersed globules (Figure 3(b)).

3.7. Refractive Index and Viscosity Studies. Isotropic nature of the formulation is demonstrated through the RI value of it. RI also explains the chemical interaction between the drug and the excipients. There were no significant differences between RI of drug loaded NE and the placebo formulation indicating the chemical stability and isotropic nature of the NE. RI of the optimized formulations was found to be 1.43 $\pm$ 0.01. While optimizing the intranasal formulations, viscosity plays a vital role as it is directly related to the residence time in the nasal mucosa. Hence in order to have a hassle free administration and better penetration and to surmount mucociliary clearance, optimum viscosity of the formulation is desired. Using an Abbe’s-type refractometer (Guru Nanak Instruments, New Delhi, India), viscosity of the NE was found to be 19.67 $\pm$ 0.25 Pa s. Newtonian type of flow characteristic of NE was inferred based on the linear correlation between shear rate and shear stress over a wide range of 0-100 s$^{-1}$ and 0-20 Pa (Figure 3(c)).

![Figure 1: Shows solubility of NRG in different (a) oils ($n=3$, mean $\pm$ SD) and (b) surfactants ($n=3$, mean $\pm$ SD).](image)

**Table 1: Miscibility of NRG in oil and surfactants with co-surfactants.**

| S. No. | Co-surfactant  | Miscibility with oils | Miscibility with Surfactants |
|--------|----------------|-----------------------|-----------------------------|
| 1      | Transcutol HP  | Clear                 | Clear                       |
| 2      | Propylene Glycol| Turbid                | Turbid                      |
| 3      | Captex 200     | Clear                 | Turbid                      |

Miscibility studies revealed that “Transcutol-HP was selected as the co-surfactant”
| Formulation code | Surfactant : co-surfactant ratio | Oil % | S<sub>mix</sub> % | Water % | Physical Stability test | Inference |
|------------------|----------------------------------|-------|----------------|--------|------------------------|-----------|
|                  |                                  |       | Surfactant     | Co-surfactant | Heating | Freeze thaw cycle | Centrifugation | |
| F1               | 4:1                              | 10    | 32             | 8       | 50  ✓✓ ✓              | Passed    |
| F2               |                                  | 20    | 25             | 5       | 50  - -               | Failed    |
| F3               | 18.18                            | 14.04 | 16.84          | 4.21    | 64.91 -              | Failed    |
| F4               | 11.94                            | 14.81 | 23.71          | 5.92    | 55.56 ✓              | Failed    |
| F5               | 11.63                            | 11.11 | 19.445         | 19.445  | 50  ✓✓ ✓              | Passed    |
| F6               | 11.11                            | 10    | 17.5           | 17.5    | 55  ✓ -               | Failed    |
| F7               | 11.63                            | 7.75  | 13.56          | 13.56   | 65.12 ✓              | Failed    |
| F8               | 11.11                            | 6.67  | 11.665         | 11.665  | 70  ✓ ✓ ✓              | Passed    |
| F9               | 11.63                            | 6.74  | 18.725         | 18.725  | 55  ✓ -               | Failed    |
| F10              | 11.11                            | 5.8   | 14.495         | 14.495  | 65.22 ✓              | Passed    |
| F11              | 10                               | 5     | 12.5           | 12.5    | 70  ✓ -               | Failed    |
| F12              | 4:1                              | 10    | 17.5           | 17.5    | 55  ✓ -               | Failed    |
| F13              |                                  | 4.21  | 13.56          | 13.56   | 65.12 ✓              | Failed    |
| F14              |                                  | 5.94  | 16.665         | 16.665  | 60  ✓ ✓              | Passed    |
| F15              |                                  | 5.8   | 14.495         | 14.495  | 65.22 ✓              | Passed    |
| F16              |                                  | 5     | 12.5           | 12.5    | 70  ✓ -               | Failed    |

NE formulation composition and physical screening studies, results of which demonstrated that the formulations prepared from the S<sub>mix</sub> ratio of 4:1 passed the physical stability test.

**Table 3: Drug loaded NE formulation composition and physical screening studies.**

| Formulation code | Surfactant : co-surfactant ratio | Oil % | S<sub>mix</sub> % | Water % | Physical Stability test | Inference |
|------------------|----------------------------------|-------|----------------|--------|------------------------|-----------|
|                  |                                  |       | Surfactant     | Co-surfactant | Heating | Freeze thaw cycle | Centrifugation | |
| F1               | 4:1                              | 10    | 32             | 8       | 50  ✓✓ ✓              | Passed    |
| F5               |                                  | 11.94 | 14.33          | 3.58    | 70.15 -               | Failed    |
| F7               |                                  | 11.63 | 18.61          | 4.65    | 65.12 ✓              | Failed    |
| F8               | 4:1                              | 11.11 | 19.445         | 19.445  | 50  ✓✓ ✓              | Passed    |
| F12              |                                  | 6.67  | 16.665         | 16.665  | 60  ✓ ✓              | Passed    |
| F14              |                                  | 5.8   | 14.495         | 14.495  | 65.22 ✓              | Failed    |
| F15              |                                  | 5     | 12.5           | 12.5    | 70  ✓ -               | Failed    |

Composition of drug loaded NE and their physical stability testing, F1 gave a clear and transparent formulation.

### 3.8. Percent Transmittance
Transmittance of the developed formulation was found to be 98.12 ± 0.07 % indicating the stability of the NE. NEs transmittance was almost equal to the aqueous phase transmittance that confirms that oil droplet was uniformly distributed with continuous phase. The formulation is transparent because the maximum size of the globules of dispersed phase was found no larger than the 1/4th of visible light’s wavelength [40].

### 3.9. Transmission Electron Microscopy
Morphology of the prepared NE was analyzed via TEM studies. It was found that the optimized formulation had spherical globules having size of 35.43 ± 4.10 nm without any sign of aggregation (Figure 3(d)). Globule size measured via TEM analysis was in compliance with the one measured through zetasizer.

### 3.10. Measurement of pH
pH of the optimized NE was found to be 6.2 ± 0.7. The pH of the NE was in adequate range for nasal drug delivery system signifying its nonirritant nature.

### 3.11. DSC Studies
DSC thermograms were obtained for pure NRG, placebo NE, and drug loaded NE (Figure 4). Pure NRG showed a sharp melting endotherm peak at 254.56°C. Thermograms of the placebo and NRG loaded NE showed a broad asymmetric endothermic peak at approximately 168°C, which may be due to evaporation of water [41]. DSC of the NRG loaded NE indicates that the drug was molecularly dispersed in the oily phase of formulation and hence the peak of the drug was not observed.

### 3.12. In Vitro Release Study
In vitro release studies were carried out to compare the release of NRG from NRG NE...
and NRG suspension. The studies revealed that the drug release from NRG NE was significantly higher in comparison to NRG suspension ($p < 0.05$). The cumulative percentage release of NRG from NE was found to be faster i.e., $88.875 \pm 2.587\%$ over a period of $8$ h in comparison to the release from NRG suspension having only $29.118 \pm 2.787\%$ drug release after $8$ h. Also, drug precipitation was observed in the dialysis bag of NRG suspension (Figure 5).

The data so obtained were further fitted to various release kinetic models, namely, zero order, first order, Higuchi, and Hixson-Crowell model to identify the drug release mechanism from NE. The results demonstrated that drug release from NE follows zero order model owing to the highest value of coefficient of correlation ($R^2$), i.e., $0.937$, which is nearer to unity (Table 4).

| Various release models | Coefficient of correlation ($R^2$) |
|------------------------|----------------------------------|
| Zero Order             | 0.937                            |
| First Order            | 0.861                            |
| Higuchi                | 0.9269                           |
| Hixon-crowell          | 0.899                            |

Data obtained from in-vitro drug release studies revealed that highest $R^2$ value was obtained in case of Zero order model.

3.13. Ex Vivo Nasal Mucosa Permeation Study. Nasal mucosa permeation studies were conducted to evaluate the permeation from the NRG NE and NRG suspension. Goat nasal mucosa was used that acted as a diffusional barrier.
mounted on Franz diffusion cell. NRG loaded NE showed maximum permeation of 85.45 ± 3.404 % at 8 h as compared to the NRG suspension which showed 24.644 ± 3.107 % of permeation (Figure 6). Drug was rapidly removed from nasal mucosa because of the mucociliary clearance ultimately causing the high permeability across the nasal mucosa which is advantageous in vivo. After 8 h of study, steady-state flux and permeability coefficient of NRG suspension and NE
through nasal mucosa were calculated to be 20.88 μgcm⁻²h⁻¹, 9.07×10⁻¹ cm²h⁻¹ and 64.78 μgcm⁻²h⁻¹, 28.16×10⁻³ cm²h⁻¹, respectively. The flux and permeability coefficient of NE were almost three times in comparison to the NRG suspension. The drug release pattern from the ex vivo permeation studies was in analogy with that of the in vitro studies. Thus, from the above study, it may be accomplished that the smaller

3.14. Antioxidant Assay by the DPPH Method. NRG has hydrogen donating capability due to which it shows the antioxidant activity on DPPH radical. NRG efficacy was estimated via determining the decline in absorbance at 515 nm. It may also be noticed visually based on the color change from purple to yellow. NRG has the ability to scavenge the free radical which decreases the concentration of DPPH. Figure shows that optimized NE exhibits the maximum percentage inhibition (95.28 ± 0.64 %) followed by the ascorbic acid (90.44 ± 1.56 %) and the NRG solution (78.32 ± 0.81 %) (Figure 7). It may also be inferred that the significant antioxidant activity (p < 0.05) of the optimized NE may be due to the synergistic effect of the combination of NRG and vitamin E.

3.15. Pharmacokinetic and Brain Targeting Studies. Pharmacokinetic parameters were estimated through the i.n. and
Table 5: Pharmacokinetic parameters of the NRG solution (i.v. and i.n.) and NE formulation after i.n. administration.

| Formulation   | Organ/Tissue | \( C_{\text{max}} \) (ng/ml) | \( T_{\text{max}} \) (h) | \( T_{1/2} \) (H) | \( K_e \) (h\(^{-1}\)) | \( \text{AUC}_{0-480} \) (ng/ml\( \times \)h) | \( \text{AUC}_{0-\infty} \) (ng/ml\( \times \)h) |
|---------------|-------------|-------------------------------|----------------|---------------|----------------|-----------------------------|-----------------------------|
| NRG sol (i.n.)| Brain       | 870.77 ± 5.4                 | 2              | 6.84 ± 0.2    | 0.1 ± 0.003    | 3352.86 ± 8.9            | 5813.18 ± 9.2              |
|               | Blood       | 775.44 ± 2.5                 | 1              | 4.63 ± 0.4    | 0.14 ± 0.04    | 1919.73 ± 6.7             | 2554.17 ± 8.1              |
| NRG NE (i.v.) | Brain       | 381.67 ± 3.1                 | 1              | 7.44 ± 0.8    | 0.09 ± 0.003   | 1599.36 ± 4.5            | 3118.87 ± 11.2             |
|               | Blood       | 2502.74 ± 4.2                | 0.5            | 3.13 ± 0.7    | 0.22 ± 0.007   | 7533.91 ± 4.5            | 9582.21 ± 7.8              |
| NRG NE (i.n.) | Brain       | 1148.64 ± 3.3                | 2              | 13.38 ± 1.1   | 0.05 ± 0.001   | 5345.13 ± 7.5            | 13543.23 ± 6.9             |
|               | Blood       | 794.33 ± 7.1                 | 2              | 10.4 ± 0.3    | 0.06 ± 0.02    | 3777.63 ± 5.3             | 8690.07 ± 8.5              |

Pharmacokinetic parameters results clearly indicated that the NRG concentration is significantly higher in optimized formulation administered via i.n. (\( p < 0.05 \)) than that of administration of optimized formulation via i.v. and NRG solution via i.v. route.

3.16. Biodistribution Studies. NRG loaded NEs following i.n. and i.v. administration along with NRG solution via i.v. route were administered on Wistar rats to study the biodistribution performed by envisaging the inherent fluorescence of ROD-123 using CLSM. Confocal images of brain obtained showed that the fluorescent dye ROD-123 reached the brain in maximum intensity from NRG loaded NEs following i.n. administration followed by ROD-123 loaded NRG solution i.n. route. ROD-123 loaded NRG NE via i.v. route showed the least intensity as shown in Figure 8.
Figure 9: The microscopic images demonstrating the histopathological condition of nasal mucosa: (a) positive control (IPA) treated mucosa shows the damaged nasal mucosa (depicted as pink) treated with isopropyl alcohol, (b) negative control (PBS pH 6.4) treated mucosa shows the intact nasal mucosa (less spots of pink) treated with isopropyl alcohol, and (c) NRG NEs treated mucosa also shows an intact epithelial layer with no traces of toxicity.

3.17. Nasal Ciliotoxicity Studies. Potential toxic effects of excipients used in the formulation were evaluated using nasal mucosa of goat. Nasal ciliotoxicity studies depicted that the mucosa treated with negative control (PBS pH 6.4) confirms no nasociliary damage and have an intact epithelial layer whereas mucosa which is treated with positive control (isopropyl alcohol) shows extensive damage (Figure 9). On the other hand, optimized formulation also showed an intact epithelial layer with no traces of toxicity.

3.18. Behavioral Activities

3.18.1. Narrow Beam Maze Test. Narrow beam test was conducted to evaluate the coordination and balance in rats (Figure 10(a)). There was significant increase in the time taken to cross the 180 cm wooden beam path (P < 0.01) in 6-OHDA treated group along with saline (228.16 ± 6.61 s) in comparison to the group which was only injected with saline (86.33 ± 7.94 s). The 6-OHDA lesion group treated with oral levodopa and NRG NE in combination showed (P < 0.01) marked improvement (108.33 ± 6.53 s).

3.18.2. Muscular Coordination Test. Rotarod test was performed to estimate the muscle coordination in the rats. Group injected with 6-OHDA showed a significant diminution in muscle coordination when compared to the group which was only treated with normal saline (p < 0.001). The maximum muscular coordination was found in the group that were injected with normal saline as they spent more time (232.5 ± 18.46 s) on the rotarod (Figure 10(b)). Muscular coordination was improved in 6-OHDA challenged group which was treated with levodopa and NRG NE simultaneously (spent 161.33 ± 10.21 s on rotarod).

3.18.3. Forced Swimming Test. A forced swimming test was conducted which showed that 6-OHDA induced rats treated with optimized formulation swam for 125.33 ± 5.88 s (Figure 10(c)). The saline treated group showed the swim behavior for 123.34 ± 3.11 s whereas the 6-OHDA induced rats attained very insignificant swim behavior of 15.09 ± 1.84 s (p < 0.05). No significant swim disability was observed in the 6-OHDA induced group treated with both NRG NE and levodopa when compared to the saline treated group.

3.18.4. Grip Strength Test. String test was conducted to measure the grip strength of the rats (Figure 10(d)). The study showed that the group induced with 6-OHDA demonstrated a very insignificant grip strength of 0.8 ± 0.83 (p > 0.05). The group treated with saline only exhibited the grip strength of 4.2 ± 0.83 which is almost statistically nonsignificant (p > 0.05) to the group which was treated with both levodopa and NEG NE, i.e., 3.8 ± 1.30.
3.18.5. Akinesia Test. The group induced with 6-OHDA treated with saline showed the inability to move due to akinesia for 236.74 ± 3.47 s (Figure 10(e)). Rats induced with 6-OHDA only and rats induced with 6-OHDA which were treated with NRG NE i.n. and levodopa orally showed akinesia for 236.74 ± 3.47 s respectively, which were found to be statistically significant (p < 0.001). However, on administration of both oral levodopa and i.n. NRG NE akinesia time was further reduced to 77.23 ± 7.95 s (p < 0.001).

3.19. Biochemical Estimation. Levels of GSH, TBARS, and SOD were compared in different formulations of NRG administered via different routes with that of the saline (Figure 11(a)). 6-OHDA induced rats showed significantly lower levels (p < 0.01) of GSH concentration (0.041 ± 0.004 μM mg⁻¹) when compared to the group treated with saline (0.187 ± 0.05 μM mg⁻¹). The NRG NE treated group showed slight increase in the GSH concentration (0.42 ± 0.04 μM mg⁻¹); however when the rats were simultaneously treated with levodopa and NRG NE together it showed a synergistic effect with a significantly higher GSH level (0.10 ± 0.002 μM mg⁻¹) (p < 0.01).

Brain tissue malonaldehyde (MDA) content was evaluated for determining the TBARS level in the brain tissue (Figure 11(b)). The MDA content in the group treated with saline only was estimated to be 0.14 ± 0.04 nM mg⁻¹ protein. 6-OHDA treated group shows a considerable increase (0.60 ± 0.06 nM mg⁻¹ protein) in the MDA content in comparison to the rats who were treated with saline only (p < 0.01). Rats treated with NRG NE via i.n. route showed small decrease in the MDA content (0.41 ± 0.02 nM mg⁻¹ protein). Group treated with both levodopa and NRG NE showed significantly
lesser MDA content (0.20 ± 0.02 nM mg⁻¹ protein) compared to the group treated with 6-OHDA (p < 0.01).

For saline treated rats, SOD level was calculated to be 27.60 ± 1.06 μM mg⁻¹ protein (Figure 11(c)). 6-OHDA induced group showed a significant dip (p < 0.01) in SOD levels (17.49 ± 2.10 μM mg⁻¹ protein). 6-OHDA induced rats treated with NRG NE i.n. showed a considerable enhancement in the levels of SOD (p < 0.01) when compared to the group which were only administered with 6-OHDA. On the other hand, the group treated with both NRG NE i.n. and oral levodopa showed a significant increase (p < 0.01) in their SOD level of 28.16 ± 2.73 μM mg⁻¹ protein.

4. Discussion

The present work was aimed to develop physically stable vitamin E loaded NRG NE to enhance its delivery to the brain via intranasal route and thus avoiding first pass metabolism and its nontargeted site circulation. Excipients were selected on the basis of solubility and miscibility studies for formulating NE. NRG was found to have the maximum solubility in a combination of Capryol 90: vitamin E (1:1) oil (i.e., 152.98 ± 2.42 mg/ml); vitamin E will have an added advantage of providing the synergistic antioxidant effect. Among the surfactants, NRG shows the maximum solubility in Tween 80 (80.52 ± 1.22 mg/ml). On the basis of miscibility studies Transcutol-HP was selected as cosurfactant as it showed miscibility with both the selected oils and surfactant. From the figures of pseudoternary phase diagrams, it was observed that area of NE is directly dependent on the S_mix ratio; hence 4:1 showed greatest NE region in comparison to the other ratios. On further increasing the S_mix ratio to 5:1 the area was somewhat decreased which indicates that further addition of surfactant will not facilitate the emulsification process. Hence, it may concluded that the NE region principally depends on the ability of a particular S_mix to meet the prerequisite for formulating NE, i.e., to get the oily phase solubilized and decrease the free energy of the system to extremely low level. Globule size is an important parameter to be studied for the efficient brain targeting of drugs. For an effective brain targeting size of the formulation should be less than 200 nm [42]. The mean globule size of optimized formulation was found out to be 38.70 ± 3.11 nm. From the studies it was concluded that increase in the S_mix ratio up to a certain level will result in the small globule size of the NE; however after which the globule size will increase with increasing S_mix [28]. This may be due to several factors like the increasing S_mix concentration up to a certain level or may be because of the decline in interfacial tension [31]. In our experiment, it was found that when S_mix was increased from 25μl to 30μl the globule size was decrease owing to the lately created droplets which have the sufficient surfactant molecules for stabilization. Alternatively, increasing the S_mix ratio to 35μl will increase the globule size because of the presence of excessive surfactant for stabilization. Alternately, increasing the S_mix ratio to 35μl will increase the globule size because of the coalescence of emulsion droplets [43]. Due to excessive S_mix gel like clumps are formed leading to the cubic phase formation which are not easily dissolvable and also cannot exist simultaneously with the NE. Droplets of fine emulsion did not occur spontaneously due to this high viscosity [44]. In addition there is a chance of cosurfactant dominating...
over surfactant over a particular level of $S_{\text{mix}}$. Similar reports have been earlier published demonstrating that upon adding surfactant to the NE system the interfacial film may condense and become stabilized, while the cosurfactant will cause the film to get expand [28].

Size distribution of NE is indicated by PDI. The PDI value of NE was found to be 0.14 ± 0.0024 respectively. Studies demonstrated that while increasing the $S_{\text{mix}}$ concentration up to a certain level will result in the decreased PDI of NE, however, on further increase the $S_{\text{mix}}$ concentration will results in increased PDI. Additionally it may be explained that the concentration of emulsifier is inversely proportional to the flow resistance that ultimately results in the NE of higher viscosity. As a result, higher coalescence rate resulting in the larger droplet sizes [39].

Physical stability of the NE was affected by zeta potential. It was found to be -27.4 ± 0.14 mV for the optimized formulation. The negative sign is an indication of strong repulsion which ultimately prevents the particle aggregation and enhances the physical stability of NE formulation [35]. In the present study it was found that concentration of oil is directly proportional to the negative value of zeta potential, i.e., higher the oil concentration more negative will be the value of zeta potential. This may be due to the steric repulsion present at the low concentrations which gets stabilized by the addition of surfactants. It may also be concluded that as the concentration of oil was increased, amount of emulsifier or surfactant becomes insufficient (as it is responsible for the coating of droplet surface), an increase in electrostatic repulsion between oil droplets was observed which ultimately leads to the increase in the negative value of zeta potential [35].

TEM study was used to determine the morphology of the optimized NE. It showed that most of the globules were spherical in shape within the nanometer range (35.43 ± 4.10 nm). TEM images further strengthen the results as the globule's size was in accordance with the size measured by zeta sizer [3, 7]. DSC studies were performed to study the dispersion of the drug. Thermogram of the optimized formulation so obtained showed an asymmetric broad endothermic peak at 168°C. The peak may be due to evaporation of water and is indicative of the molecular dispersion of the drug in the oil phase [41].

In vitro release studies over a period of 8 h confirmed an initial burst release (Figure 5) and sustained releases go after. Presence of nanodroplets on the surface of NEs caused the formulation to release in bulk initially. However, the latter sustained release was because of the drug's release at oil-water interface from the oily core which was obstructed by the dialysis bag and aqueous medium and [26, 31]. The results of in vitro kinetic release demonstrated that drug release from NE follows zero order model owing to the highest value of coefficient of correlation ($R^2$), i.e., 0.937, which is nearer to unity.

Goat nasal mucosa was used to conduct the ex vivo permeation studies which demonstrated that NE showed higher drug permeation through nasal mucosa in comparison to the drug solution. This higher drug permeation of NE is due to its nanodroplet size which increases the solubilization of the drug. Also, existence of a penetration enhancer i.e., Tween 80 on to the surface of NE also enhances the drug permeability via nasal mucosa [28].

The antioxidant activity of the optimized formulation and NRG solution was compared with that of the ascorbic acid (standard antioxidant) using the DPPH assay method. Optimized NRG NE showed the maximum percentage inhibition owing to the ability of NRG to donate hydrogen which showed the antioxidant effect.

In vivo studies verified that the concentration of NRG in brain when administered via i.n. as NRG NE was significantly higher (p<0.05) as compared to the i.n. administration of NRG solution and NRG NE administered via i.v. route. This may be due to the direct transportation of drug via olfactory route thus bypassing BBB with the usage of Tween 80 and Transcutol-HP which ultimately enhances the penetration of drug via nasal mucosa [28]. DTE% and DTP% of NRG NE was considerably higher (p<0.05) in comparison to the NRG solution suggestive of better brain targeting efficiency of NRG NE due to the considerable direct nose-to-brain delivery, nanodroplets size and lipophilicity of NE [43, 44]. There was a significant enhancement (p<0.05) in absolute BA of NRG NE via i.n. in comparison to the NRG NE via i.v. and NRG solution via i.n. owing to the small globule size, elevated drug release and increased residence time of NE in the nasal cavity. NE transportation via transcellular pathway through olfactory neurons to the brain through various endocytic pathways of sustentacular or neuronal cells in the olfactory membrane was facilitated by the small globule size of NE. Additionally, the usage of Tween-80 and Transcutol-HP in the NE considerably enhanced the nasal absorption of the NRG as a result of p-glycoprotein (P-gp) inhibition thus improved the BA of NRG [43, 44]. Hence, the present study showed that NRG could be transported directly to the brain via i.n. delivery of NRG NE, accordingly enhancing drug concentration in the brain.

CLSM study showed that the ROD-123- NRG-NE (i.n.) concentration was higher in brain as compared to the ROD-123- NRG-NE (i.v.) and ROD-123- NRG-Solution (i.n.) because of the intranasal delivery and thus circumventing the BBB. It might be due to the drug’s increased permeability as lipidic nanocarrier and inhibition of P-gp efflux (by formulation excipients) which expels out ROD-123 solution [20, 30].

Nasal ciliotoxicity studies using goat nasal mucosa investi- rate the presence of an intact epithelial layer, i.e., when goat nasal mucosa treated with both negative control and NRG NE it does not shows any nasociliary damage [44] (Figure 9). It is also an indicative of the excipients used in formulating NE was nonirritating, safe and nontoxic.

PD symptoms were induced using 6-OHDA in rats which were then reversed by administering NRG formulations by different routes. In the present study, there was appreciable rapid improvement in behavioral activity due to restoration of dopamine following treatment with NRG NE (i.n.). This is likely due to the antioxidant effect of NRG which ultimately leads to the reversal of PD symptoms. NE showed improved NRG brain delivery in comparison to the solution, which may
be attributed to the fact that there was more drug permeation through the nasal mucosa. Small globule size of the NE offers more surface area for the interaction between the drug and the cells, hence more drug uptake through the nasal mucosa. Studies showed that ROS are involved in the pathogenesis of PD. Antioxidants help in eradicating the generated ROS. 6-OHDA induces formation of ROS in brain of rats after injection. Optimized NE formulation showed better behavioral activity via i.n. route owing to the synergistic effect of NRG and Vitamin E. Results of the present study demonstrated that NRG solution (i.v.) have no significant effect on reversal of 6-OHDA induced PD as it did not find an easy passage through BBB, on the other hand NRG solution when administered via intranasal route demonstrated effective antagonization of 6-OHDA induced akinesia, hypolocomotion and related symptoms. These interpretations confirmed the effectiveness of NRG given via the olfactory route as lower doses of the drug is required for the pharmacological actions [15, 20]. The study showed that the treatment of 6-OHDA induced rats with NE along with the standard therapy (levodopa) was successful in reversing the effects induced with 6-OHDA including muscle coordination, grip strength, enhancing swimming activity. Hence, intranasal administration of NRG NE avoids first pass metabolism thereby protecting it from the nasal metabolizing enzymes and enhancing the uptake of NRG to the brain, avoiding systemic circulation and hence enhancing the amount of NRG in the brain and improving brain bioavailability.

5. Conclusion

In the present study, physically stable vitamin E loaded NRG NE was formulated. Experimental data showed that there was maximum in vitro along with significant high ex vivo trans-nasal mucosal flux. Also, concentration of the drug in the brain was found to be higher proving the targeting efficiency of NE through i.n. route. The study showed that the treatment of 6-OHDA induced rats with NE along with the standard therapy (levodopa) was successful in reversing the effects induced with 6-OHDA including muscle coordination, grip strength, and enhancing swimming activity. Hence, intranasal administration of NRG NE avoids first pass metabolism, thereby protecting it from the nasal metabolizing enzymes and enhancing the uptake of NRG to the brain, avoiding systemic circulation and hence enhancing the amount of NRG in the brain and improving brain bioavailability.

Abbreviations

NRG: Naringenin
NE: Nanoemulsion
PD: Parkinson’s disease
PDI: Polydispersity index
CNS: Central nervous system
BBB: Blood Brain Barrier
TEM: Transmission electron microscopy
CLSM: Confocal laser scanning fluorescence microscopy
NBM: Narrow beam maze
PMS: Postmitochondrial supernatant
GSH: Glutathione
EDTA: Ethylenediaminetetraacetic acid
TCA: Trichloroacetic acid
TBARS: Thiobarbituric acid-reactive substances
TBA: Thiobarbituric acid
SOD: Superoxide dismutase
LOD: Limit of detection
LOQ: Limit of quantification

Data Availability

All data are provided in full in the results section of this paper.

Disclosure

The authors hereby declared that this research did not receive any specific funding. No funder was involved in the manuscript writing, editing, approval, or decision to publish.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] GBD 2016 Parkinson’s Disease Collaborators, “Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of disease study 2016,” The Lancet Neurology, vol. 17, pp. 939–953, 2018.
[2] Y. Wang, H. Xu, Q. Fu, R. Ma, and J. Xiang, “Protective effect of resveratrol derived from Polygonum cuspidatum and its liposomal form on nigral cells in Parkinsonian rats,” Journal of the Neurological Sciences, vol. 304, no. 1-2, pp. 29–34, 2011.
[3] K. Chopra, B. Medhi, and A. Prakash, “Granulocyte-colony stimulating factor improves Parkinson’s disease associated with co-morbid depression: an experimental exploratory study,” Indian Journal of Pharmacology, vol. 4, pp. 612–615, 2013.
[4] A. H. Schapira and C. W. Olanow, “Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson’s disease,” Annals of Neurology, vol. 53, no. S3, pp. S149–S159, 2003.
[5] J. D. O’Reilly, T. A. B. Sanders, and H. Wiseman, “Flavonoids protect against oxidative damage to LDL in vitro: use in selection of a flavonoid rich diet and relevance to LDL oxidation resistance ex vivo,” Free Radical Research, vol. 33, no. 4, pp. 419–426, 2000.
[6] K. J. Raj and K. Shalini, “Flavonoids—a review of biological activities,” Investigational New Drug, vol. 36, pp. 668–676, 1999.
[7] A. Scalbert and G. Williamson, “Dietary intake and bioavailability of polyphenols,” Journal of Nutrition, vol. 130, no. 8, pp. 2073S–2085S, 2000.
[8] J. Jayaraman, M. Veerappan, and N. Namasivayam, “Potential beneficial effect of naringenin on lipid peroxidation and antioxidant status in rats with ethanol-induced hepatotoxicity,” Journal of Pharmacy and Pharmacology, vol. 61, no. 10, pp. 1383–1390, 2009.
[9] H. L. Madsen, C. M. Andersen, L. V. Jørgensen, and L. H. Skibsted, “Radical scavenging by dietary flavonoids. A kinetic
study of antioxidant efficiencies,” European Food Research and Technology, vol. 211, no. 4, pp. 240–246, 2000.

[10] J. Yu, L. Wang, R. L. Walzem, E. G. Miller, L. M. Pike, and B. S. Patil, “Antioxidant activity of citrus limonoids, flavonoids, and coumarins,” Journal of Agricultural and Food Chemistry, vol. 53, no. 6, pp. 2009–2014, 2005.

[11] M. Kumar, A. Misra, A. K. Babbar, A. K. Mishra, P. Mishra, and K. Pathak, “Intranasal nanoemulsion based brain targeting drug delivery system of risperidone,” International Journal of Pharmaceutics, vol. 358, no. 1-2, pp. 285–291, 2008.

[12] S. T. Prajapati, S. P. Pathak, J. H. Thakkar, and C. N. Patel, “Nanoemulsion based intranasal delivery of risperidone for nose to brain targeting,” Bulletin of Pharmaceutical Research, vol. 5, no. 1, pp. 6–13, 2015.

[13] S. Ganta, H. Devalapally, and M. Amiji, “Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation,” Journal of Pharmaceutical Sciences, vol. 99, no. 11, pp. 4630–4641, 2010.

[14] F. F. Campos, A. C. Calpena Campmany, G. R. Delgado, O. L. Serrano, and B. C. Naveros, “Development and characterization of a novel nystatin-loaded nanoemulsion for the buccal treatment of candidiasis: ultrastructural effects and release studies,” Journal of Pharmaceutical Sciences, vol. 101, no. 10, pp. 3739–3752, 2012.

[15] K. Gurpret and S. K. Singh, “Review of nanoemulsion formulation and characterization techniques,” Indian Journal of Pharmaceutical Sciences, vol. 80, no. 5, 2018.

[16] Y. Liu, F. Wei, Y. Wang, and G. Zhu, “Studies on the formation of bifenthrin oil-in-water nano-emulsions prepared with mixed surfactants,” Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 389, no. 1-3, pp. 90–96, 2011.

[17] C. V. Pardeshi and V. S. Belgamwar, “Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: An excellent platform for brain targeting,” Expert Opinion on Drug Delivery, vol. 10, no. 7, pp. 957–972, 2013.

[18] W.-Y. Ong, S.-M. Shalini, and L. Costantino, “Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders,” Current Medicinal Chemistry, vol. 21, no. 37, pp. 4247–4256, 2014.

[19] L. Illum, “Nasal drug delivery—possibilities, problems and solutions,” Journal of Controlled Release, vol. 87, no. 1-3, pp. 187–198, 2003.

[20] R. Pangeni, S. Sharma, G. Mustafa, J. Ali, and S. Baboota, “Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress,” Nanotechnology, vol. 25, no. 48, 2014.

[21] M. F. Haider, S. Khan, B. Gaba et al., “Optimization of rivastigmine nanoemulsion for enhanced brain delivery: in-vivo and toxicity evaluation,” Journal of Molecular Liquids, vol. 255, pp. 384–396, 2018.

[22] A. W. Khan, S. Kotta, S. H. Ansari, R. K. Sharma, and J. Ali, “Self-nanoemulsifying drug delivery system (SNEDDS) of the poorly water-soluble grapefruit flavonoid Naringenin: Design, characterization, in vitro and in vivo evaluation,” Drug Delivery, vol. 22, no. 4, pp. 552–561, 2015.

[23] P. Khadka, J. Ro, H. Kim et al., “Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability,” Asian Journal of Pharmaceutical Sciences, vol. 9, no. 6, pp. 304–316, 2014.

[24] V. Puri, “A study on nano emulsion (Emulgel),” International Journal of Advanced Pharmaceutical Sciences, vol. 1, no. 3, pp. 27–55, 2018.

[25] B. M. Shah, M. Misra, C. J. Shishoo, and H. Padh, “Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization,” Drug Delivery, vol. 22, no. 7, pp. 918–930, 2015.

[26] J. Ahmad, S. R. Mir, K. Kohli et al., “Solid-nanoemulsion pre-concentrate for oral delivery of paclitaxel: formulation design, biodistribution, and scintigraphy imaging,” BioMed Research International, vol. 2014, no. 4, article no. 984756, 2014.

[27] M. Srivastava, K. Kohli, and M. Ali, “Formulation development of novel in situ nanoemulgel (NEG) of ketoprofen for the treatment of periodontitis,” Drug Delivery, vol. 23, no. 1, pp. 154–166, 2016.

[28] H. Bshara, R. Osman, S. Mansour, and A. E.-H. A. El-Shamy, “Chitosan and cyclodextrin in intranasal microemulsion for improved brain bisoprolol hydrochloride pharmacokinetics in rats,” Carbohydrate Polymers, vol. 99, pp. 297–305, 2014.

[29] S. Kumar, J. Ali, and S. Baboota, “Design Expert supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease,” Nanotechnology, vol. 27, no. 43, 2016.

[30] M. A. Bhat, M. Iqbal, A. Al-Dhiyan, and F. Shakeel, “Carvone Schiff base of ionazid as a novel antitumor agent: nanoemulsion development and pharmacokinetic evaluation,” Journal of Molecular Liquids, vol. 203, pp. 111–119, 2015.

[31] M. Kumar, K. Pathak, and A. Misra, “Formulation and characterization of nanoemulsion-based drug delivery system of risperidone,” Drug Development and Industrial Pharmacy, vol. 35, no. 4, pp. 387–395, 2009.

[32] S. Sood, K. Jain, and K. Gowthamarajan, “Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment,” Colloids and Surfaces B: Biointerfaces, vol. 113, pp. 330–337, 2014.

[33] H. Thakkar, A. Patel, and N. Chauhan, “Formulation and optimization of mucoadhesive microemulsion containing mir-tazapine for intranasal delivery,” Chronicles of Young Scientists, vol. 5, no. 1, pp. 25–32, 2014.

[34] P. Shrivastava, K. Vaibhav, R. Tahassum et al., “Anti-apoptotic and anti-inflammatory effect of Piperine on 6-OHDA induced Parkinson's rat model,” The Journal of Nutritional Biochemistry, vol. 24, no. 4, pp. 680–687, 2013.

[35] D. S. Bernardi, T. A. Pereira, R. N. Maciel et al., “Formation and stability of oil-in-water nanoemulsions containing rice bran oil: in vitro and in vivo assessments,” Journal of Nanobiotechnology, vol. 9, no. 44, pp. 1–9, 2011.

[36] P. O. Fernagut, E. Diguet, B. Bioulac, and F. Tison, “MPTP and MPTP components screening and selection: a technical note,” AAPS PharmSciTech, vol. 10, no. 1, pp. 69–76, 2009.

[37] V. Yemparala, A. A. Damre, V. Manohar et al., “Effect of the excipient concentration on the pharmacokinetics of PM18104, a novel antimicrobial thiazolyl cyclic peptide antibiotic, following intravenous administration to mice,” Results in Pharma Sciences, vol. 4, pp. 34–41, 2014.

[38] N. González, R. Simarro, M. C. Molina, L. F. Bautista, L. Delgado, and J. A. Villa, “Effect of surfactants on PAH
biodegradation by a bacterial consortium and on the dynamics of the bacterial community during the process,” *Bioresource Technology*, vol. 102, no. 20, pp. 9438–9446, 2011.

[40] N. Belhaj, F. Dupuis, E. Arab-Tehrany et al., “Formulation, characterization and pharmacokinetic studies of coenzyme Q10 PUFA's nanoemulsions,” *European Journal of Pharmaceutical Sciences*, vol. 47, no. 2, pp. 305–312, 2012.

[41] V. Polychniatou and C. Tzia, “Study of formulation and stability of co-surfactant free water-in-olive oil nano- and submicron emulsions with food grade non-ionic surfactants,” *Journal of the American Oil Chemists’ Society*, vol. 91, no. 1, pp. 79–88, 2014.

[42] S. M. Dordevic, T. S. Radulovic, N. D. Cekic et al., “Experimental design in formulation of diazepam nanoemulsions: physicochemical and pharmacokinetic performances,” *Journal of Pharmaceutical Sciences*, vol. 102, no. 11, pp. 4159–4172, 2013.

[43] H. S. Mahajan, M. S. Mahajan, P. P. Nerkar, and A. Agrawal, “Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting,” *Drug Delivery*, vol. 21, no. 2, pp. 148–154, 2014.

[44] S. Md, S. Haque, M. Fazil et al., “Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method,” *Expert Opinion on Drug Delivery*, vol. 11, no. 6, pp. 827–842, 2014.